The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by
The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by ELGEMS, which are sold by Elscint as VariCam and by GE Medical Systems as Millennium VG. Elscint plans to begin shipments of VTransACT for VariCam in the first quarter of 1999, according to a spokesperson for the company. ELGEMS also received 510(k) clearance for a set of ultra-high-energy collimators, called VPC-94. The collimators are designed to be used on VariCam for FDG cardiac imaging.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.